This site is intended for health professionals only

Published on 10 June 2009

Share this story:
Twitter
LinkedIn

Lung cancer test developed

teaser

The test combines results of DNA analysis with other risk factors such as age, diseases such as bronchitis and emphysema and family lung cancer history, said University of Auckland associate professor Robert Young.

“All smokers face an increased risk of developing lung cancer, among a host of other serious health problems, but for some individuals the risk is much greater than for others,” Young said.

“With this test, doctors will be able to identify those at greatest risk while there is still time to help.”

The test obtains a patient’s DNA from a simple mouth swab.

Lung cancer is the most lethal of common cancers, with half of all sufferers dying within a year of diagnosis and 80 percent within two years.

The risk can be lowered by quitting smoking, and survival rates improve dramatically if the disease is detected early.

Young said research suggested many smokers had an optimistic bias, believing the disease would affect other smokers rather than them.

Early evidence suggested that identifying higher-risk patients may also allow better monitoring for early detection of the disease.

The test, trade named Respiragene, generates a score putting smokers and ex-smokers into categories of moderate, high risk and very high risk of developing lung cancer.

Average smokers with a moderate risk are 20 to 30 times more likely to develop lung cancer than non-smokers, and about one in 10 average smokers will develop lung cancer.

People categorised as high risk are about four times more likely than an average smoker to get lung cancer, and those with a very high risk are about 10 times more likely to get the disease.

“The test results may help patients decide, with their doctor, to get help to quit smoking and how closely they should be monitored for lung cancer going forward,” said Young.

The test, developed by a company from the University of Auckland called Synergenz Bioscience, is expected to be available worldwide before the end of the year.

University of Auckland



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn